T1	Participants 91 131	patients with superficial bladder cancer
T2	Participants 192 354	the efficacy and side effects of intravesical mitoxantrone instillation with those of doxorubicin in superficial bladder cancer following transurethral resection.
T3	Participants 363 440	Sixty-three patients were randomized into mitoxantrone and doxorubicin groups
T4	Participants 442 513	Most of the patients enrolled were elderly people (mean age, 71 years).
T5	Participants 867 948	Thirty-three patients received mitoxantrone, whereas 30 patients used doxorubicin
